Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results

Gyre Therapeutics (NASDAQ:GYRE) announced its quarterly earnings results on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.04), FiscalAI reports. The business had revenue of $29.11 million during the quarter, compared to analyst estimates of $26.49 million. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%.

Gyre Therapeutics Trading Up 4.2%

GYRE stock traded up $0.27 during midday trading on Friday, hitting $6.67. The stock had a trading volume of 67,603 shares, compared to its average volume of 52,226. The firm has a market cap of $743.64 million, a P/E ratio of -74.10 and a beta of 1.92. Gyre Therapeutics has a 1-year low of $5.44 and a 1-year high of $9.42. The business has a fifty day moving average price of $6.25 and a two-hundred day moving average price of $7.07.

Insider Buying and Selling

In other Gyre Therapeutics news, COO Weiguo Ye sold 12,820 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $6.15, for a total transaction of $78,843.00. Following the completion of the sale, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. This trade represents a 1.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in GYRE. Bank of America Corp DE increased its holdings in Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Gyre Therapeutics by 84.6% in the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after buying an additional 3,244 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Gyre Therapeutics during the 4th quarter worth approximately $77,000. Finally, Wells Fargo & Company MN grew its position in shares of Gyre Therapeutics by 132.4% during the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after buying an additional 7,361 shares during the period. Institutional investors own 23.99% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on GYRE shares. Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Weiss Ratings downgraded Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $17.00.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.